Worldwide, there are over one billion people who suffer from depression, anxiety, PTSD, and addiction and this has created an industry within the pharmaceutical world that is extremely lucrative, but ripe for disruption. The global mental health market is expected to reach $6 trillion by 2030 and there are now 47 publicly traded companies focusing on psychedelics. This presents an enormous opportunity for those early investors who are able to look past the historical negative stigma associated with many psychedelics and PsychedeicInvest.com is a must-visit site for anyone looking to invest in the psychedelic industry.

Below is a summary of news related to 3 of the 4 psychedelic R&D companies in our MunAiMarkets portfolio. If you would like to subscribe to their daily newsletter from which we provide the following information, please go here.